Products

Approved in the E.U.

Pixantrone (PIXUVRI®) was granted conditional marketing approval in the E.U. in May 2012 as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.

PIXUVRI is not approved in the U.S.

Learn more about PIXUVRI.

You Are Leaving CTI BioPharma

You have selected a link to a third-party website. This link is provided solely as a convenience to you and not as an endorsement by CTI BioPharma of such third-party website. CTI BioPharma is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.

Continue to the Requested Site
Return to CTI BioPharma

Hello! We are pleased to announce that Cell Therapeutics has changed its name to

Enter Site